Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy
Claudia Friedl,1 Emanuel Zitt2 1Department of Internal Medicine, Clinical Division of Nephrology, Medical University of Graz, Graz, 2Department of Internal Medicine III, Nephrology and Dialysis, Feldkirch Academic Teaching Hospital, Feldkirch, Austria Abstract: Secondary hyperparathyroidism (sHPT) i...
Saved in:
Main Authors: | Friedl C (Author), Zitt E (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2018-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and Safety of Etelcalcetide in Hemodialysis Patients with Moderate to Severe Secondary Hyperparathyroidism
by: Paola Monciino, et al.
Published: (2022) -
Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide
by: Cozzolino M, et al.
Published: (2017) -
Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis
by: Ye J, et al.
Published: (2018) -
THE CARDIOVASCULAR EFFECTS OF CINACALCET IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM
by: Sungjin Chung, et al.
Published: (2012) -
Comparison between paricalcitol versus cinacalcet therapy in the management of secondary hyperparathyroidism among prevalent hemodialysis patients
by: Maha A. Behairy, et al.
Published: (2022)